347 related articles for article (PubMed ID: 34779535)
1. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Kramer JR; Natarajan Y; Dai J; Yu X; Li L; El-Serag HB; Kanwal F
Hepatology; 2022 Jun; 75(6):1420-1428. PubMed ID: 34779535
[TBL] [Abstract][Full Text] [Related]
2. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Li L; Dai J; Natarajan Y; Yu X; Asch SM; El-Serag HB
Hepatology; 2020 Mar; 71(3):808-819. PubMed ID: 31675427
[TBL] [Abstract][Full Text] [Related]
3. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
Chen J; Song S; Li X; Bian D; Wu X
Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
[TBL] [Abstract][Full Text] [Related]
4. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
5. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
6. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Sacco M; Ribaldone DG; Saracco GM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
[TBL] [Abstract][Full Text] [Related]
7. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease.
Zou B; Odden MC; Nguyen MH
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):435-444.e6. PubMed ID: 35158055
[TBL] [Abstract][Full Text] [Related]
8. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
Vilar-Gomez E; Calzadilla-Bertot L; Wong VW; Castellanos M; Aller-de la Fuente R; Eslam M; Wong GL; George J; Romero-Gomez M; Adams LA
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):136-145.e6. PubMed ID: 32389886
[TBL] [Abstract][Full Text] [Related]
9. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC).
Chu J; Cholankeril G; Yu X; Rana A; Natarajan Y; El-Serag HB; Kramer J; Kanwal F
Dig Dis Sci; 2023 Mar; 68(3):1060-1070. PubMed ID: 35759159
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Noureddin M; Rinella ME
Clin Liver Dis; 2015 May; 19(2):361-79. PubMed ID: 25921668
[TBL] [Abstract][Full Text] [Related]
11. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
12. Letter to the editor: Effect of diabetes medications and glycemic control on risk of HCC in patients with NAFLD.
Zhou Y; Chu W; Wu X; Zhou H; Niu B; Chen Z; Mi Y; Li P
Hepatology; 2022 Aug; 76(2):E48-E49. PubMed ID: 35366349
[No Abstract] [Full Text] [Related]
13. Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia.
Chen HH; Lin MC; Muo CH; Yeh SY; Sung FC; Kao CH
Medicine (Baltimore); 2015 Jun; 94(24):e1013. PubMed ID: 26091447
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
17. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
18. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD).
Doycheva I; Loomba R
Adv Ther; 2014 Jan; 31(1):30-43. PubMed ID: 24385405
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
[TBL] [Abstract][Full Text] [Related]
20. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
